Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Apr 8;37(6):1311–1323. doi: 10.1038/s41375-023-01885-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 6 — A B-cell depletion of ibrutinib and nivolumab combination (Ibru + Nivo) compared to ibrutinib monotherapy (Ibru) (n = 17), with a significant benefit in most resistant patients (n = 7). B Effect of adding nivolumab to ibrutinib treatment in in vivo responder (R) or non-responder (NR) patients, represented as the fold change of B-cell depletion induced by the combination compared to Ibrutinib monotherapy. C Interferon gamma (IFNγ) concentration in PDLS supernatants comparing ibrutinib monotherapy or in combination with Nivolumab in MCL-PDLS. D Granzyme B secretion comparing ibrutinib monotherapy with ibrutinib and nivolumab combo, in sensitive or resistant patients to the combination. Cytometric Bead Array (CBA) analysis of cell culture supernatants was used in (C) and (D) (n = 12).